Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
Bryan Unger, Director of Business Development at Microvascular Therapeutics, reposted from NuvOx Therapeutics on LinkedIn:
”Proud to share that the first patient has been enrolled in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion.
Stroke is one of the leading drivers of long-term disability and healthcare costs, with lifelong care representing a substantial burden for patients, families, and health systems.
Our Phase IIa data for NanO₂ showed strong potential in reducing this burden.
Reaching the first patient enrolled is a critical milestone.
We are grateful to the clinical teams and partners who are advancing this work.”
Quoting NuvOx Therapeutics‘s post:
”We have enrolled the first patient in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion (LVO).
NOVEL is a multicenter, randomized, placebo-controlled study funded by the NIHR (National Institute for Health and Care Research)–MRC EME Programme, and co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.
This milestone advances NanO₂, designed to rapidly improve tissue oxygenation, toward addressing one of the most severe and costly forms of stroke.
We thank our clinical collaborators and funding partners as we activate additional sites and accelerate enrollment.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show